Aspen Alert’s Post

View organization page for Aspen Alert, graphic

4,527 followers

Biogen Pays $1.15 Billion Upfront to Acquire HI-Bio Biogen announced this week that it is expanding its presence in the immunology space through a potential $1.8 billion deal to buy privately held biotech Human Immunology Biosciences, also known as HI-Bio. Under the terms of the agreement, Biogen will pay $1.15 billion upfront and pledge up to $650 million in potential milestone payments. The companies expect to complete the transaction in the third quarter of 2024, pending antitrust clearances and other customary closing conditions. At the center of the acquisition is HI-Bio’s lead candidate felzartamab, originally developed by Morphosys, which the biotech is developing as a treatment for IgA nephropathy (IgAN) and primary membranous nephropathy (PMN), as well as antibody-mediated rejection (AMR) in kidney transplant recipients. https://lnkd.in/dQTfqy2j #aspenalert #biotech #bioprocess

Biogen Beefs Up Immuno Pipeline with Potential $1.8B HI-Bio Acquisition | BioSpace

Biogen Beefs Up Immuno Pipeline with Potential $1.8B HI-Bio Acquisition | BioSpace

biospace.com

To view or add a comment, sign in

Explore topics